SCHEMBL2943232

SCHEMBL2943232

c1ccc(CCNc2cc(-c3cc4ccccc4o3)c3nccn3n2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 5/20 0.57
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP1A2 P05177 1/20 0.43
JAK2 O60674 1/20 0.39
PTK2 Q05397 1/20 0.39
APP P05067 3/20 0.39
PDE4D Q08499 1/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
ADORA2A P29274 1/20 0.35
FYN P06241 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940430 0.90 MKNK1 (0.45) MKNK1NPC1RAB9AMEN1KMT2A
SCHEMBL2947497 0.84 MKNK1 (0.46) MKNK1NPC1RAB9AJAK2PTK2
SCHEMBL2948003 0.83 MKNK1 (0.55) MKNK1ALDH1A1KDM4EHSD17B10ADORA2A
SCHEMBL2950868 0.80 MKNK1 (0.56) MKNK1JAK2ADORA2AFYNPIM1
SCHEMBL2943235 0.77 MKNK1 (0.67) MKNK1NPC1RAB9AMEN1KMT2A
SCHEMBL2943231 0.72 MKNK1 (1.00) MKNK1FYN
SCHEMBL3869341 0.66 CXCR1 (0.42) MKNK1SMN1; SMN2F2RL3
SCHEMBL2940434 0.66 MKNK1 (0.54) MKNK1NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL27513658 0.63 CYP1A2 (1.00) MKNK1NPC1RAB9ACYP1A2APP
SCHEMBL3867949 0.63 FAAH (0.37) MKNK1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 MKNK1 144/4885NPC1 3970/4885RAB9A 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.